Equities analysts expect that Cascadian Therapeutics Inc (NASDAQ:CASC) will report earnings per share (EPS) of ($0.29) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Cascadian Therapeutics’ earnings. Cascadian Therapeutics reported earnings per share of ($0.47) during the same quarter last year, which would suggest a positive year-over-year growth rate of 38.3%. The company is scheduled to report its next quarterly earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Cascadian Therapeutics will report full year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.14). For the next year, analysts expect that the business will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.22) to ($0.69). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Cascadian Therapeutics.
Cascadian Therapeutics (NASDAQ:CASC) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. During the same period in the previous year, the company posted ($0.09) earnings per share.
Cascadian Therapeutics (NASDAQ:CASC) traded up $0.07 on Wednesday, hitting $3.63. The stock had a trading volume of 264,300 shares, compared to its average volume of 275,250. Cascadian Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $4.99. The stock has a market cap of $193.14, a P/E ratio of -2.71 and a beta of 2.29.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CASC. Schwab Charles Investment Management Inc. purchased a new position in shares of Cascadian Therapeutics in the 2nd quarter valued at about $225,000. Rhumbline Advisers purchased a new position in shares of Cascadian Therapeutics in the 2nd quarter valued at about $143,000. State of Wisconsin Investment Board purchased a new position in shares of Cascadian Therapeutics in the 2nd quarter valued at about $104,000. Bank of New York Mellon Corp grew its stake in Cascadian Therapeutics by 649.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 154,575 shares of the biopharmaceutical company’s stock worth $574,000 after buying an additional 133,962 shares during the last quarter. Finally, Teachers Advisors LLC purchased a new position in Cascadian Therapeutics during the 2nd quarter worth approximately $252,000. Institutional investors and hedge funds own 80.33% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://theolympiareport.com/2018/01/10/420463.html.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.